The Utilization of Alpha-1 Anti-trypsin (A1AT) in Infectious Disease Monitoring and Treatment

Irene L. Indalao, Agustiningsih Agustiningsih, Eka Pratiwi, Kartika Dewi Puspa, Hartanti Dian Ikawati, Ririn Ramadhan

Center for Research and Development of Biomedical and Basic Technology of Health, National Institute of Health Research and Development, Ministry of Health Republic of Indonesia

ABSTRACT

Alpha one anti-trypsin (A1AT) is a major serine protease inhibitor found circulating in human blood. A1AT related studies mainly focus on A1AT potential biomarker as well as therapeutic target in non-infectious diseases. Their findings indicate A1AT beneficial features may also be applied for monitoring and treating infectious disease. However, only a few studies have reviewed A1AT’s useful properties as a biomarker and therapeutic agent for infectious diseases. This narrative review aims to summarize growing evidences that support the idea of utilizing A1AT as a tool for monitoring and therapy for infectious diseases.

A1AT showed potential as a biomarker for a wide spectrum of infectious disease, from virus, bacteria, to parasite. Its level and functionality were proposed to predict risk for disease susceptibility or progression and to indicate response therapy. As promising therapeutic agent in various infectious diseases, the administration of A1AT has shown antimicrobial activity, immunomodulatory and anti-apoptotic effect, in addition to more familiar function, suppressing excessive proteolysis.

The broad utilization of A1AT, both as biomarker and therapeutic agent, in studies on infectious diseases seems promising. However, there are issues need to be investigated further before establishing its feasibility as a monitoring and therapy tool against infection diseases. J Microbiol Infect Dis 2019; 9(1): 51-58.

Keywords: Alpha-1 anti-trypsin, virus, bacteria, biomarker, drug, infection, parasite, protozoa, review

INTRODUCTION

Alpha one antitrypsin (A1AT) belongs to serine protease inhibitor superfamily. It is synthesized in the endoplasmic reticulum of hepatocytes, bronchial and type II alveolar epithelial and endothelial cells and secreted into the circulation system, lung lavage, interstitium of the lung and body fluids such as saliva, tears, breast milk, urine, and semen [1,2]. The rise of A1AT level above normal level (plasma: 20-53 mM, interstitial fluid 10-40 mM, epithelial lining fluid (ELF) 2-5 mM) signifies a pathological condition [3]. In normal condition, the lung produces an enzyme such as elastase to ensure that it is free from pollutants or pathogens. However, due to its proteolytic activity, elastase can be dangerous as it can breakdown lung structures if not regulated properly [4]. The main role of the A1AT is to maintain lung integrity and function as the principal inhibitor of elastase [5]. SERPINA1 is the gene that regulates A1AT expression. The mutation of this gene results in defective A1AT. The most common mutation forms are Z type A1AT, and the milder form, S type A1AT [6,7]. The Z type mutation prevents A1AT to mature and form secretion especially in liver and lung. The S type is an unstable protein with shortened serum half-life [8]. Another rarely found mutation, the null mutation, abolishes A1AT production [9]. People with such mutation have higher risk of developing lung and liver disease [8-9].

The roles of A1AT have been studied and reviewed extensively in non-infectious disease settings. The reviews highlight beneficial effect of A1AT in treating cystic fibrosis (CF), chronic
obstructive pulmonary disease (COPD), collagen induced arthritis (CIA), graft versus host disease (GVHD), diabetes, acute myocardial infarction, inflammatory bowel disease, acute liver failure, and cancer [2,7,10-12]. The therapeutic effects of augmenting A1AT observed in these studies include suppressing pro-inflammatory cytokines, reducing inflammatory cell infiltration, increasing anti-inflammatory cytokines, and reducing apoptosis. Whether A1AT has similar potential against infectious disease has not been reviewed yet. In this review, we aim to identify studies emphasize A1AT as a useful tool for monitoring and therapy for infectious diseases, and to recommend future research to be considered before implementing A1AT utilization into practice. The findings emphasize A1AT beneficial features that can be applied for infectious disease management are summarized in Table 1 and Table 2.

A1AT utilization as a biomarker to predict susceptibility and disease progression of certain infection

A1AT has been proposed as a risk biomarker for certain infection since in its deficient state, one becomes more susceptible to infection. This has been indicated by Acquired Immunodeficiency Syndrome (AIDS) studies in which patients with A1AT deficiency had higher risk to get infected by HIV compared to healthy control [13-16]. Furthermore, study presented evidence that A1AT level in Bronchoalveolar Lavage Fluid (BALF) could be a predictive factor for HIV infected patients to develop emphysema [17]. It showed a high level of A1AT serum in HIV patients with A1AT deficient condition predisposes them to the development of emphysema. The analysis revealed that circulating protein could not function as well as its normal form [17]. This finding suggests the term of “deficiency” in this context does not only refer to the amount of A1AT in the host but also the functionality of this inhibitor.

Another study observed similar potential in Mycobacterium abscessus infection. The abnormal A1AT phenotype predisposes patients to develop non tuberculous mycobacterium infection (NTBI) [18]. The potential use of A1AT to predict someone’s susceptibility to HIV and NTBI opens the possibility that A1AT could be used to predict susceptibility to other infectious diseases in which its pathogen entry or release depends on host protease activation and whether its level can be used to predict progression of the infection.

The rise of A1AT level in the A1AT non deficient infected person compared to healthy control indicate an acute phase infection, as shown in the case of Dengue virus, Mycobacterium tuberculosis, Mycobacterium abscessus, and malaria infection [19-28,31,43-44]. Moreover, the fall inA1AT level may reflect the response after the therapy. A study in Uganda exhibited TB (tuberculosis) patients initially had a high level of A1AT in their sera. By the end of either standard TB therapy (rifampin, isoniazid, pyrazinamide, and ethambutol) or experimental therapy (rifapentine used as substitute to rifampin), the level of A1AT serum in the recovering patients’ sera had decreased [25]. While A1AT is not the only acute phase reactant measured and known to decrease after successful treatment, the finding shows A1AT is useful to monitor patient response to TB therapy.

Many studies have investigated whether A1AT can be utilized as a biomarker to determine the severity level of the infection of dengue fever (DF) and malaria. One of them found high A1AT and NS1 proteins in the sera of all of DF and dengue hemorrhagic fever (DHF) patients, while only lower level seen in healthy controls [19]. Other study, however, did not observe significant change of A1AT level in non-severe dengue and severe dengue infection [26]. This indicates it is less effective to use A1AT as biomarker to predict the dengue severity. Meanwhile, a research group incubated synthetic hemozoin, a protein secreted by Plasmodium falciparum during hemolysis into circulation, within the sera of malaria patients and healthy controls and analyzed serum proteins that bind with the hemozoin. They found A1AT as one of the major hemozoin binding proteins identified only in malaria patient samples [27]. Therefore, the interaction of host and pathogen protein may support A1AT as a malaria biomarker. Although it is still not clear whether the fold increase of A1AT can give information of severity degree of malaria...
infection, their data showed a trend that severe malaria has higher A1AT level than the mild one.

**A1AT utilization as a therapeutic agent to overcome infection**

The antiviral properties of A1AT have been attributed to its ability to bind and inactivate the virus fusion protein. A study demonstrated Virus Inhibitor Peptide (VIRIP), the most potent fraction of A1AT, inhibits HIV gp41 fusion peptide that disrupts HIV entry [28]. This finding was supported by other group’s work where they nominated C-terminus of A1AT as an essential function domain mediates the inhibition of HIV entry by interacting with gp41 [29].

Another antiviral property of A1AT is its ability to bind and inhibit some host proteases used by the viruses to cleave their proteases to ensure their replication and spread within the host cells. The F protein of *Measles* virus cleaves host protease furin. Using human glioma cells which stably expressing constructed A1AT, Alpha-1-Antitrypsin Portland (Alpha1-PDX), A1AT was demonstrated to inhibit F0 cleavage by furin, resulting in significant reduction of infectious virus titers [30]. HCMV (*Human cytomegalovirus*) infection has been displayed to be inhibited in a similar way. Utilizing Alpha1-PDX, furin was completely blocked, preventing the maturation of HCMV envelope protein called glycoprotein B (gB) and dramatically reducing infectious HCMV in vitro [31]. Furthermore, *Lassa virus* precursor glycoprotein, preGP-C, was found to be recognized and subsequently cleaved by the host protease, S1P (sphingosine 1 phosphate). By constructing A1AT to imitate S1P recognition motives owned by *Lassa virus* glycoprotein, they demonstrated that A1AT intervene the proteolytic activation of *Lassa virus* preGP-C by S1P. As a consequence, the virus maturation cannot proceed, making the released noninfectious virions in vitro [32, 33].

Meanwhile, the interaction between A1AT and Human Rhinovirus (HRV) seems to be unique. Instead of binding and inactivating HRV 3C protease, which involves in HRV replication and maturation, A1AT suppresses HRV host receptor gene expression, namely, intercellular adhesion molecule-1 (ICAM-1) [I]. In turn, A1AT treatment on infected bronchial epithelial cell culture reduces viral load [34]. Moreover, A1AT administration has been proven to suppress the inflammation factors such as IL-8 in infected brushed bronchial epithelial cells and its homolog in mouse, KC (keratinocyte chemotactrant) in wild type C57BL/6 mice [35].

A1AT also has antibacterial ability. A1AT provides protection to human alveolar epithelial cell type II and mouse lung from *Pseudomonas aeruginosa* infection and subsequent inflammation [36]. The study corroborates with other that discovered aerosolized purified human A1AT treatment significantly suppressed lung inflammation and advanced bacterial clearance in rat [37]. Furthermore, A1AT prevents short palate, lung, and nasal epithelium clone 1 (SPLUNC1) from being degraded by neutrophil elastase, preventing the infected mice from losing their antimicrobial proteins [38]. These studies propose A1AT protective effect is due to its ability to inhibit neutrophil elastase which not only prevent the host from extreme increase of inflammatory cytokines but also helps the host maintains its cell membrane integrity. Interestingly, there was a study showed that *Pseudomonas aeruginosa* also produces elastase which can potentially inactivate A1AT before it makes a complex with trypsin or neutrophil elastase [39-41]. However, their findings have not been confirmed in the cell culture and animal studies. Another study investigated the potential of A1AT in suppressing *Mycobacterium abscessus* infection in human macrophages. A1AT could block rapidly growing mycobacterium (RGM) uptake by monocytes derived from healthy human peripheral blood mononuclear cells (PBMC) [18]. A potential therapy of A1AT for patients with sustained growing mycobacteria pulmonary disease was proposed.

In *Escherichia coli* (E. coli) infection, the use of A1AT as therapeutic agent seems promising. Using in vitro system, a study showed A1AT can bind with *Escherichia coli* protein EspB, inhibiting it from integrating with host cell membrane and subsequent bacteria protein invasion into cell cytosol, hence, preventing hemolysis [42]. In vivo, A1AT administration to purified lipopolysaccharide derived from E.coli (LPS) induced acute lung injury mice results in decreased LPS induced inflammation. The similar finding was shown in human lung
microvascular endothelial cell system. The unique property of A1AT found in this study is that the anti-inflammatory effective was not due to the usual neutrophil elastase inhibition activity but from suppression of factors related to endoplasmic reticulum stress pathway [43]. Another demonstrated tissue protective effect of A1AT was in accordance with reduced bacterial burden infection in mouse model [44].

A1AT treatment also has also been proposed to counteract the infection of Moraxella catarrhalis, a gram negative bacteria causing acute otitis and respiratory tract infection in human. A study revealed A1AT anti-inflammatory effect that is independent from A1AT proteolytic activity in purified tonsillar B cell culture [45] since both active and inactive form of A1AT, could inhibit MID-induced tonsillar B cell proliferation and IL-6 release. Unfortunately, there has not been updated study exploring A1AT effect upon Moraxella catarrhalis yet since this report. The A1AT potential against parasite infection also described in previous studies [46,47]. They focused on Cryptosporidium parvum, a parasite causing diarrhea in human and severe morbidity in immune-compromised host. Its spread through oocysts phase, which can stand wide range of environmental exposure, highlights the importance to eradicate its oocysts. In earlier study, they found A1AT can be used as anti-cryptosporidiosis when A1AT gains access into Cryptosporidium parvum oocyst and prevent its excystation in vitro [46]. On the other hand, A1AT inhibition activity is less effective against its sporozoite phase. To overcome this issue, they combined the human A1AT treatment with paromomycin and obtained more promising result in their subsequent study [47].

Altogether, these studies provide evidences to support the idea of proposing human A1AT as an alternative infectious disease treatment in non-deficient setting. They also imply administration of A1AT may help A1AT deficient infected patients to counteract the damage caused by the infection.

Table 1. Use of A1AT in viral infections.

<table>
<thead>
<tr>
<th>Infectious Pathogen</th>
<th>A1AT utilization</th>
<th>Therapeutic Agent [Ref No]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Virus</strong></td>
<td><strong>Biomarker</strong></td>
<td><strong>Therapeutic Agent [Ref No]</strong></td>
</tr>
<tr>
<td>HIV</td>
<td>low level in serum precedes HIV infection; deficient patient has higher risk to get infected by HIV [13-16]; high level in serum but deficient in terms of function predisposes HIV patients with emphysema development [17]</td>
<td>inhibits VIRIP to cleave with gp41 [28,29]</td>
</tr>
<tr>
<td>Rhinovirus</td>
<td>no reference available yet</td>
<td>inhibits HRV receptor induction [34] and anti inflammatory [35]</td>
</tr>
<tr>
<td>Dengue virus</td>
<td>high level indicates acute phase infection [19;20,21]; higher level in DF and DHF cases compared to healthy control. A trend of higher level as the severity degree increases but not significant [26]</td>
<td>no reference available yet</td>
</tr>
<tr>
<td>Lassa virus</td>
<td></td>
<td>inhibits S1P to activate Lassa’s preGP-C [32,33]</td>
</tr>
<tr>
<td>Measles</td>
<td>no reference available yet</td>
<td>inhibits furin to cleave Measles F protein [30]</td>
</tr>
<tr>
<td>Human cytomegalovirus</td>
<td></td>
<td>inhibits furin to cleave virus maturation protein, gB</td>
</tr>
</tbody>
</table>
Table 2. Use of A1AT in bacterial and parasitic infections.

<table>
<thead>
<tr>
<th>Infectious Pathogen</th>
<th>A1AT utilization</th>
<th>Therapeutic Agent [Ref No]</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacteria</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>no reference available yet</td>
<td>anti-inflammatory [42,44], prevents tissue damage [44], inhibits hemolysis [42]</td>
<td></td>
</tr>
<tr>
<td>Mycobacterium abscessus</td>
<td>predispose patient to develop NTBI [18]</td>
<td>bacteria reduction [18]</td>
<td></td>
</tr>
<tr>
<td>Mycobacterium tuberculosis</td>
<td>increase in TB patients compared to control participant [22]; decline at the end of TB therapy and burden disease [25]</td>
<td>no reference available yet</td>
<td></td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>anti-inflammatory [36-38] and prevents tissue damage [38]</td>
<td>A1AT is inhibited by elastase, but in certain condition [39-41]</td>
<td></td>
</tr>
<tr>
<td>Moraxella catarrhalis</td>
<td>full length active or inactive A1AT can suppress inflammation [45]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Legionella pneumophila</td>
<td>no reference available yet</td>
<td>Legionella’s TDP inhibited A1AT first before could complex with serine protease (48)</td>
<td></td>
</tr>
<tr>
<td>Serratia marcescens</td>
<td>no reference available yet</td>
<td>Serratia’s 56K protease inhibit A1AT [49]</td>
<td></td>
</tr>
<tr>
<td>Yersinia enterocolitica</td>
<td>binding of A1AT and Yersinia’s protein did not affect A1AT activity to inhibit elastase [51]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>Staphylococcus’ STAP cleaves A1AT; this cannot happen if the binding site has been occupied by elastase [40]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Parasites</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasmodium falciparum</td>
<td>dysregulated during febrile stage; acute infection [23-24]; not clear but there is trend that the fold increase of A1AT is higher in severe malaria than mild one [27]</td>
<td>no reference available yet</td>
<td></td>
</tr>
<tr>
<td>Plasmodium vivax</td>
<td>dysregulated during febrile stage; acute infection [23,24]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cryptosporidium parvum</td>
<td>inhibits oocyst excystation; more efficient when combined with paromomycin [46,47]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trichomonas vaginalis</td>
<td>no reference available yet</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Most studied therapeutic feature of A1AT has been its ability to counteract and block the activity of certain proteases secreted as a response to remove infectious pathogens, which at the same time; can dissociate the cell membranes integrity, resulting in structural damage. Second, it interacts directly with certain host pathogen receptors or pathogen’s structural protein. The availability and functionality of A1AT will interfere and inhibit the interaction between the pathogen and the host factors.

This is usually applicable to microorganisms whose entry or release needs activation of host proteases and the outcome can affect their infectivity. Third, the A1AT can modulate inflammation in several ways; suppressing the pro-inflammatory cytokines and chemokines, activating the increase production of anti-inflammatory cytokines, suppressing factors of endoplasmic reticulum stress pathway. In a particular case, A1AT can inhibit the microorganism life stage development directly, such as preventing oocyst excystation. Implications for future research and studies exploiting A1AT for infectious disease management.

The evidences that A1AT can be useful to indicate acute phase infection of various microorganisms are accumulating. While this can be advantageous, it cannot be used to identify specific pathogen, considering A1AT level change was found not only in one infection. On the other hand, A1AT level alteration can be used to describe the disease stage the patient is in. Thus, its level measurement may become practical in monitoring treatment response. Additionally, measuring A1AT level may be recommended to predict the risk of patients to be susceptible to certain infection or disease progression.

Despite promising preliminary evidences of using A1AT to counteract infection, it may seem sensible to nominate A1AT as alternative for infectious disease treatment. However, it is important to cautiously calculate its feasibility. Not all A1AT beneficial effect during infection has been verified in nonhuman primate or human model. Also, there are proteases secreted by the infectious pathogens able to inactivate A1AT protease activity like Tissue Destructive Protease (TDP) secreted by \textit{Legionella pneumophila} and \textit{Staphylococcus aureus’} proteinase (STAP) \cite{37, 48}. They inactivate A1AT only if the binding site of A1AT has not been occupied by host’s serine protease. Additionally, \textit{Serratia marcescens’} metalloprotease can degrade A1AT \cite{49}. Meanwhile, \textit{Trichomonas vaginalis} outer protein (YopM) has a specific binding site for A1AT, but the biological function of their interaction has not been clarified \cite{51}. These findings suggest; A1AT may not be suitable for treating all infectious diseases. Researchers should comprehend the pathogenesis of the pathogen before considering A1AT as potential drug. Another issue needs clarification is whether additional A1AT will compromise the host ability to clear the pathogen, since it will suppress the elastase production. Lastly, we recommend future studies should investigate whether A1AT therapy can be advantageous in co-infection settings.

\textbf{Conclusion}

In the future, public health and clinical practitioners may benefit from harnessing beneficial features of A1AT, considering the recent growing indications that A1AT can be utilized as a biomarker and therapeutic agent for particular infectious diseases. Nevertheless, further investigations, especially for drug development, are needed to prevent any adverse event for the patient.

\textbf{ACKNOWLEDGMENTS}

We would like to thank Ni Ketut Susilarini, Vivi Setiawaty, and Dorothy Southern for their valuable suggestions in developing this manuscript.

\textbf{Declaration of Conflicting Interests:} The authors declare that they have no conflict of interest.

\textbf{Funding statement:} The current work received no external funds.

\textbf{REFERENCES}


